Inhibiting a key protein in the tumor microenvironment using Noxxon’s experimental agent NOX-A12 may enhance the clinical activity of immunotherapies…
Articles by Inês Martins, PhD
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met its primary endpoint in a Phase 3 trial as a potential…
A three-drug therapy combination consisting of Darzalex (daratumumab) with Revlimid (lenalidomide) and Decadron (dexamethasone) shows real potential in…
High-risk multiple myeloma patients may benefit markedly from galinpepimut-S, an experimental immunotherapy from SELLAS Life Sciences, following autologous stem cell…
Robots can do all sorts of tasks to improve cancer treatment and now researchers have added room cleaning to the…
The U.S. Food and Drug Administration (FDA) is giving priority review to a supplemental Biologics License Application (sBLA) to…
The communication between multiple myeloma cells and healthy bone marrow cells is an important step in disease progression, researchers have…
Treatment of newly diagnosed multiple myeloma patients with a combination of Kyprolis (carfilzomib), Alkeran (melphalan), and prednisone does not yield superior outcomes, compared to…
BioInvent International has received further patent protection in China, Japan, and Russia covering the use of BI-505 in cancer patients…
Newly diagnosed multiple myeloma patients who are using statins have lower mortality rates than those who don’t, a large population-based cohort…